Table 1.

Characteristics of patients who had MSK-IMPACT testing prior to EGFR TKI therapy (n=200) or after EGFR TKI therapy (n=136) or both (n=38)

Clinical characteristics	Pre EGFR-TKI N (%)	Post EGFR-TKI N (%)	Paired samples N (%)
Total	200	136	38
Age
Median (range)	63 (23–89)	61 (29–86)	62 (34–84)
Sex
Male	66 (33)	95 (70)	11 (29)
Female	134 (67)	41 (30)	27 (71)
Smoking
Never-smoker	118 (59)	79 (58)	22 (58)
Former smoker	82 (41)	57 (42)	16 (42)
Median pack-yr (range)	6 (1–125)	0 (0–110)	0 (0–30)
Histology			Before TKI		After TKI
Adenocarcinoma	200 (100)	133 (97.8)	38 (100)*		37 (97)
Small cell carcinoma	0 (0)	2 (1.5)	0 (0)		1 (3)
Large cell neuroendocrine	0 (0)	1 (0.7)	0 (0)		0 (0)
EGFR mutation
EGFR T790M	0 (0)	70 (52)	0 (0)	16 (42)
Exon 19 deletion	90 (45)	78 (57)	17 (45)
L858R	72 (36)	43 (32)	15 (39)
Exon 20 insertions	7 (3.5)	1 (0.7)	0 (0)
Exon 18 deletion	5 (2.5)	4 (3)	3 (8)
Exon 19 insertion	3 (1.5)	1 (0.7)	1 (3)
L861Q	6 (3)	2 (1.5)	0 (0)
G719A	3 (1.5)	2 (1.5)	0 (0)
L747P	3 (1.5)	0 (0)	0 (0)
E709X+G719X	4 (2)	0 (0)	0 (0)
G719X+S768I	2 (1)	3 (2)	0 (0)
G719X+L861Q	3 (1.5)	0 (0)	0 (0)
EGFR-KDD	2 (1)	2 (1.5)	2 (5)
Prior treatment
Erlotinib	0 (0)	128 (94)	0 (0)	36 (95)
Afatinib	0 (0)	6 (4)	0 (0)	2 (5)
Dacomitinib	0 (0)	2 (1)	0 (0)	0 (0)